Xenetic Biosciences, Inc. Closes $15.0 Million Underwritten Public Offering and Completes Acquisition of Innovative CAR T Technology Platform Jul 22, 2019
Xenetic Biosciences, Inc. (Nasdaq: XBIO) Announces Pricing of $15.0 Million Underwritten Public Offering Jul 17, 2019
Xenetic Biosciences, Inc. Reports First Quarter 2019 Financial Results and Provides Corporate Update May 13, 2019
Xenetic Biosciences, Inc. Strengthens Scientific Advisory Board with Appointment of Guenther Koehne, M.D., Ph.D. May 2, 2019
Xenetic Biosciences, Inc. (NASDAQ: XBIO) Announces Agreement to Acquire Innovative CAR T Technology Platform Mar 4, 2019
Xenetic Biosciences Reports 2017 Third Quarter Financial Results and Provides Corporate Update Nov 15, 2017
Xenetic Biosciences Enters Into Sublicense Agreement Related to its PolyXen™ Technology with Baxalta Inc., a Wholly-owned Subsidiary of Shire plc Nov 2, 2017
